AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Warby Parker, gold miners, copper miners
U.S. STOCKS ON THE MOVE-Bark, Babylon, Digital Turbine
Akari rises on rare pediatric disease designation for blood disorder drug
Brief: Akari Therapeutics Granted FDA Rare Pediatric Disease Designation Of Nomacopan
Brief: Akari Therapeutics Announces Receipt Of Nasdaq Minimum Bid Price Notification
Brief: Akari Therapeutics Announces Receipt Of Nasdaq Minimum Bid Price Notification
Brief: Akari Therapeutics PLC Files Prospectus Relates To Resale, By Selling Shareholders Of Up To An Aggregate Of 2.78 Bln Ordinary Shares
Brief: Akari Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Pipeline Progress
Akari Therapeutics tanks on $12.75 mln share offering
Brief: Akari Therapeutics Announces $12.75 Million Registered Direct Offering
Brief: Akari Therapeutics Narrows Pipeline Focus
Brief: Akari Therapeutics Reports Q1 2022 Results
Brief: Akari Therapeutics Announces First Patient To Complete Course Of Treatment In The Phase III Part A Clinical Trial Of Investigational Nomacopan
Brief: Akari Therapeutics Appoints Melissa Bradford-Klug As Chief Operating Officer
Brief: Akari Therapeutics Reports Full Year 2021 Financial Results And Highlights Clinical Progress
Brief: Akari Therapeutics Announces Publication Of Phase Ii Data Of Investigational Nomacopan For The Treatment Of Bullous Pemphigoid (BP) In Jama Dermatology
Brief: Akari Presents Results From Two Preclinical Development Programs Of Long-Acting Pas-Nomacopan
Brief: Akari Therapeutics Announces New Data Supporting Use Of Drug Candidate Votucalis
Brief: Akari Therapeutics Appoints Rachelle Jacques As CEO And President